In high-grade serous ovarian cancer, cisplatin-resistant cells exhibit elevated fatty acid uptake and CPT1A-mediated FAO, while CPT1A inhibition effectively restores chemosensitivity [48]. This evidence concerns the gene CPT1A and ovarian serous adenocarcinoma.